JP2005516050A - 急性心筋梗塞のための複合治療 - Google Patents
急性心筋梗塞のための複合治療 Download PDFInfo
- Publication number
- JP2005516050A JP2005516050A JP2003563560A JP2003563560A JP2005516050A JP 2005516050 A JP2005516050 A JP 2005516050A JP 2003563560 A JP2003563560 A JP 2003563560A JP 2003563560 A JP2003563560 A JP 2003563560A JP 2005516050 A JP2005516050 A JP 2005516050A
- Authority
- JP
- Japan
- Prior art keywords
- levosimendan
- myocardial infarction
- acute myocardial
- pharmaceutically acceptable
- thrombolytic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
実施例1.静脈内注入用濃縮溶液
(a)レボシメンダン 2.5mg/ml
(b)Kollidon PF12 10mg/ml
(c)クエン酸 2mg/ml
(d)脱水エタノール ad 1ml(785mg)
濃縮溶液は、滅菌された製造容器内で、撹拌しながら、クエン酸、Kollidon PF121およびレボシメンダンを脱水エタノールに溶解することにより製造された。得られたバルク溶液(bulk solution)を、滅菌フィルター(0.22μm)で濾過した。ついで、滅菌濾過されたバルク溶液を、無菌的に(5mlおよび10mlの充填容量で)8mlおよび10ml注入バイアルに充填し、ゴム閉塞栓で密封した。
(a)t−PA 2.0%(w/w)
(b)リン酸 20%(w/w)
(c)L−アルギニン 78%(w/w)
成分を、標準的な方法で混合、凍結乾燥、および滅菌した。20、50または100mgのt−PA/投与形態(バイアル)を含有する凍結乾燥物は、注入のために滅菌水で、たとえば1mg/mlの濃度の溶液に再形成される。
硬質ゼラチンカプセルサイズ3
レボシメンダン 2.0mg
ラクトース 198mg
カプセル形態における医薬製剤は、レボシメンダンをラクトースと混合し、粉状混合物を硬質ゼラチンカプセルに入れることによって、製造された。
急性心筋梗塞患者の死亡率における該組み合わせの効果
急性心筋梗塞を患っている患者は、プラシーボ、または6、12もしくは24μg/kgのボーラスと、そののちの0.1、0.2もしくは0.4μg/kg/分の注入を用いた、レボシメンダンの6時間注入を5日間受けた。患者は、血栓溶解療法を受けたかどうかによって、分類した。180日の死亡率を測定した。結果を表1に示す。該組み合わせにより、急性心筋梗塞患者の死亡率が相乗的に低下することが分かる。
Claims (6)
- 有効量の血栓溶解剤と、レボシメンダンまたはその薬学的に許容し得る塩とを、同時に、個別に、または連続的に、急性心筋梗塞の治療が必要な患者に投与することを含む急性心筋梗塞の治療方法。
- 有効量の血栓溶解剤と、レボシメンダンまたはその薬学的に許容し得る塩とを、同時に、個別に、または連続的に、急性心筋梗塞の治療が必要な患者に投与することを含む、急性心筋梗塞患者の死亡率を低下させる方法。
- 活性成分として、血栓溶解剤、およびレボシメンダンまたはその薬学的に許容し得る塩を、個別にまたはともに含有する複合製剤としての医薬品。
- 活性成分として、血栓溶解剤、およびレボシメンダンまたはその薬学的に許容し得る塩を含有する医薬組成物。
- 同時、個別、または連続的投与用の複合製剤の製造における、活性成分としての血栓溶解剤、およびレボシメンダンまたはその薬学的に許容し得る塩の使用。
- 急性心筋梗塞患者の死亡率を低下させるための薬剤の製造における、活性成分としての血栓溶解剤、およびレボシメンダンまたはその薬学的に許容し得る塩の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20020197A FI20020197A0 (fi) | 2002-02-01 | 2002-02-01 | Yhdistelmä akuutin myokardiilisen infarktin hoitoon |
PCT/FI2003/000078 WO2003063870A1 (en) | 2002-02-01 | 2003-01-31 | A combination treatment for acute myocardial infarction |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005516050A true JP2005516050A (ja) | 2005-06-02 |
Family
ID=8563019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003563560A Pending JP2005516050A (ja) | 2002-02-01 | 2003-01-31 | 急性心筋梗塞のための複合治療 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20050255096A1 (ja) |
EP (1) | EP1478362B1 (ja) |
JP (1) | JP2005516050A (ja) |
CN (1) | CN1291718C (ja) |
AT (1) | ATE306267T1 (ja) |
AU (1) | AU2003201980B2 (ja) |
BR (1) | BR0307317A (ja) |
CA (1) | CA2474430C (ja) |
DE (1) | DE60301862T2 (ja) |
DK (1) | DK1478362T3 (ja) |
ES (1) | ES2249707T3 (ja) |
FI (1) | FI20020197A0 (ja) |
HK (1) | HK1077215A1 (ja) |
IL (1) | IL163091A (ja) |
MX (1) | MXPA04007345A (ja) |
NZ (1) | NZ534221A (ja) |
PL (1) | PL212241B1 (ja) |
WO (1) | WO2003063870A1 (ja) |
ZA (1) | ZA200406085B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR298901A0 (en) | 2001-02-07 | 2001-03-08 | McComb Foundation, Inc., The | Cell suspension preparation technique and device |
FI20040674A0 (fi) | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
WO2006087420A2 (en) * | 2005-02-18 | 2006-08-24 | Orion Corporation | A method for treating heart failure |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
WO2008082871A1 (en) * | 2006-12-28 | 2008-07-10 | Orion Corporation | Formulations of levosimendan for parenteral administration |
AU2013205148B2 (en) * | 2013-03-14 | 2014-10-30 | AVITA Medical Americas, LLC | Systems and methods for tissue processing and preparation of cell suspension therefrom |
US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
CN115518037A (zh) * | 2022-10-14 | 2022-12-27 | 上药东英(江苏)药业有限公司 | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07506354A (ja) * | 1992-05-06 | 1995-07-13 | オリオン−ユヒチュメ オサケ ユキチュア | 抗虚血薬剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5626601A (en) * | 1995-10-27 | 1997-05-06 | Gary Gershony | Vascular sealing apparatus and method |
US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
-
2002
- 2002-02-01 FI FI20020197A patent/FI20020197A0/fi unknown
-
2003
- 2003-01-31 MX MXPA04007345A patent/MXPA04007345A/es active IP Right Grant
- 2003-01-31 DK DK03700828T patent/DK1478362T3/da active
- 2003-01-31 CA CA2474430A patent/CA2474430C/en not_active Expired - Fee Related
- 2003-01-31 AT AT03700828T patent/ATE306267T1/de active
- 2003-01-31 AU AU2003201980A patent/AU2003201980B2/en not_active Ceased
- 2003-01-31 DE DE60301862T patent/DE60301862T2/de not_active Expired - Lifetime
- 2003-01-31 NZ NZ534221A patent/NZ534221A/xx not_active IP Right Cessation
- 2003-01-31 EP EP03700828A patent/EP1478362B1/en not_active Expired - Lifetime
- 2003-01-31 PL PL371741A patent/PL212241B1/pl not_active IP Right Cessation
- 2003-01-31 CN CNB038030918A patent/CN1291718C/zh not_active Expired - Fee Related
- 2003-01-31 US US10/502,981 patent/US20050255096A1/en not_active Abandoned
- 2003-01-31 ES ES03700828T patent/ES2249707T3/es not_active Expired - Lifetime
- 2003-01-31 JP JP2003563560A patent/JP2005516050A/ja active Pending
- 2003-01-31 BR BR0307317-3A patent/BR0307317A/pt not_active Application Discontinuation
- 2003-01-31 WO PCT/FI2003/000078 patent/WO2003063870A1/en active IP Right Grant
-
2004
- 2004-07-19 IL IL163091A patent/IL163091A/en not_active IP Right Cessation
- 2004-07-29 ZA ZA200406085A patent/ZA200406085B/en unknown
-
2005
- 2005-10-20 HK HK05109333A patent/HK1077215A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07506354A (ja) * | 1992-05-06 | 1995-07-13 | オリオン−ユヒチュメ オサケ ユキチュア | 抗虚血薬剤 |
Non-Patent Citations (5)
Title |
---|
JPN6009034540, 今日の治療指針1997年度版, 19970615, pp. 335−338 * |
JPN6009034543, Bernard J. Gersh, "Current issues in reperfusion therapy", The American Journal of Cardiology, 19981022, Vol. 82, No. 8, Sup. 1, pp. 3P−11P * |
JPN6009034545, Judy R. Kersten et al., "Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KAT", Anesthesia & Analgesia, 200001, Vol. 90, No. 1, pp. 5−11 * |
JPN6009034548, POLSON J B et al., "Cyclic nucleotide phosphodiesterases and vascular smooth muscle.", Annual Review of Pharmacology and Toxicology, 1996, Vol. 36, pp. 403−427 * |
JPN6009034551, Hideyuki Takaoka et al., "Beneficial effects of a Ca 2+ sensitizer, MCI−154, on the myocardial oxygen consumption?cardiac outp", American Heart Journal, 199703, Vol. 133, No. 3, pp. 283−289 * |
Also Published As
Publication number | Publication date |
---|---|
PL371741A1 (en) | 2005-06-27 |
CA2474430C (en) | 2010-09-28 |
DK1478362T3 (da) | 2005-11-14 |
ES2249707T3 (es) | 2006-04-01 |
CN1291718C (zh) | 2006-12-27 |
AU2003201980B2 (en) | 2006-12-07 |
CN1625398A (zh) | 2005-06-08 |
EP1478362A1 (en) | 2004-11-24 |
IL163091A (en) | 2012-06-28 |
NZ534221A (en) | 2007-06-29 |
DE60301862D1 (de) | 2006-02-23 |
EP1478362B1 (en) | 2005-10-12 |
DE60301862T2 (de) | 2006-07-20 |
MXPA04007345A (es) | 2004-11-26 |
ATE306267T1 (de) | 2005-10-15 |
FI20020197A0 (fi) | 2002-02-01 |
US20050255096A1 (en) | 2005-11-17 |
WO2003063870A1 (en) | 2003-08-07 |
ZA200406085B (en) | 2005-10-06 |
HK1077215A1 (en) | 2006-02-10 |
BR0307317A (pt) | 2005-01-04 |
PL212241B1 (pl) | 2012-08-31 |
CA2474430A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005239847B2 (en) | A method for the prevention of thromboembolic disorders | |
JP2010065060A (ja) | 心不全処置のための複合治療 | |
JP2005516050A (ja) | 急性心筋梗塞のための複合治療 | |
AU2003201980A1 (en) | A combination treatment for acute myocardial infarction | |
KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
Jacob | Pulse steroids in hematologic diseases | |
JP2004512376A (ja) | 虚血性障害の処置用医薬品の製造のためのメラガトランの使用 | |
EP1848434A2 (en) | A method for treating heart failure | |
US20100249103A1 (en) | combination treatment | |
US20060052450A1 (en) | Use of l-carnitine for the treatment of cardiovascular diseases | |
JP2008533109A (ja) | 利尿を促進するための複合治療 | |
HU207455B (en) | Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent | |
NZ543221A (en) | Anti-rotation foot for strainer post | |
WO2011027021A1 (en) | A method for the treatment of hypertension | |
JP4965791B2 (ja) | 敗血症性ショックの治療方法 | |
EP0527720B1 (en) | Therapeutic agents | |
CZ20014685A3 (cs) | Lék pro léčbu nebo prevenci vazospazmu koronárního ątěpu | |
JP2007238609A (ja) | 糖尿病患者における虚血性疾患の予防のための医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091013 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100113 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100330 |